Canaccord Genuity reissued their buy rating on shares of Radius Health Inc (NASDAQ:RDUS) in a research note published on Sunday morning, MarketBeat reports. They currently have a $85.00 price objective on the biopharmaceutical company’s stock.

In related news, major shareholder Growth N. V. Biotech acquired 38,259 shares of the firm’s stock in a transaction on Friday, January 22nd. The stock was bought at an average cost of $31.67 per share, with a total value of $1,211,662.53. Following the transaction, the insider now owns 4,360,399 shares of the company’s stock, valued at $138,093,836.33. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction on Wednesday, January 13th. The shares were bought at an average cost of $39.90 per share, with a total value of $1,995,000.00. Following the completion of the transaction, the insider now directly owns 4,322,140 shares in the company, valued at approximately $172,453,386. The disclosure for this purchase can be found here.

A number of hedge funds recently bought and sold shares of RDUS. CenturyLink Investment Management Co bought a new stake in Radius Health during the fourth quarter worth $252,000. Quantitative Systematic Strategies acquired a new stake in Radius Health during the fourth quarter valued at approximately $302,000. Salzhauer Michael boosted its stake in Radius Health by 66.7% in the fourth quarter. Salzhauer Michael now owns 7,500 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 3,000 shares in the last quarter. Meeder Asset Management acquired a new stake in Radius Health during the fourth quarter valued at approximately $515,000. Finally, Russell Frank Co acquired a new stake in Radius Health during the fourth quarter valued at approximately $538,000.

Shares of Radius Health (NASDAQ:RDUS) opened at 32.03 on Friday. Radius Health has a 52-week low of $28.76 and a 52-week high of $84.64. The stock has a 50 day moving average price of $49.51 and a 200-day moving average price of $62.79. The stock’s market capitalization is $1.37 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.10. During the same quarter last year, the firm posted ($0.59) earnings per share. On average, equities research analysts anticipate that Radius Health will post ($2.41) EPS for the current fiscal year.

A number of other research analysts also recently commented on RDUS. Vetr upgraded Radius Health from a buy rating to a strong-buy rating and set a $81.68 price objective on the stock in a report on Wednesday, October 7th. Cowen and Company restated an outperform rating on shares of Radius Health in a research note on Sunday, October 18th. Zacks Investment Research downgraded Radius Health from a hold rating to a sell rating in a research note on Monday, November 9th. Jefferies Group dropped their price target on Radius Health from $79.00 to $77.00 in a research note on Wednesday, November 18th. Finally, Cantor Fitzgerald restated a buy rating on shares of Radius Health in a research note on Friday, December 11th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $77.07.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (NASDAQ:RDUS), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

12 Month Chart for NASDAQ:RDUS

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.